RSS Feed Print
Nanobody for Alzheimer's Moves Closer to Clinical Trials
Posted: Thursday, April 26, 2012 8:25 PM
Joined: 12/6/2011
Posts: 3326

From Alzheimer's Daily News:

(Source: MarketWatch) - Ablynx today announced that Boehringer Ingelheim has submitted a Clinical Trials Application to the European regulatory authorities to start a Phase I clinical trial with a Nanobody® for the treatment of Alzheimer's disease.

In January 2007, the two companies announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies against a single disease target.


Dr. Edwin Moses, CEO and Chairman of Ablynx, commented: "We are excited that Boehringer Ingelheim has already submitted a CTA for this Nanobody. This development candidate has the potential to be a first-in-class therapy for Alzheimer's disease and demonstrates the power of our Nanobody platform. We look forward to seeing this program enter the clinic over the coming months."


Go to full story: